James Healy has been a General Partner of Sofinnova Investments, a venture capital firm, since June 2000. Prior to June 2000, he held various positions at Sanderling Ventures, Bayer Healthcare Pharmaceuticals (as successor to Miles Laboratories) and ISTA Pharmaceuticals, Inc. Jim represents Sofinnova also on the board of directors of Ascendis, Coherus, Edge, Natera, Audentes, Iterum and Nucana. Previous investments and board memberships include Anthera Pharmaceuticals (ANTH), Cellective Therapeutics (acquired by AstraZeneca), CoTherix (CTRX, acquired by Actelion), Durata Therapeutics (DRTX, acquired by Actavis), InterMune (ITMN, acquired by Roche), Movetis (MOVE, acquired by Shire), Nextwave Pharmaceuticals (acquired by Pfizer), Novacea (NOVC, merged with Transcept), Preglem (acquired by Gideon Richter), Prestwick (acquired by Biovail), and Salveo Specialty Pharmacy (acquired by Catamaran).
Jim holds an MD and a PhD in Immunology from the Stanford School of Medicine and holds a B.A. in molecular biology and a B.A. in Scandinavian Studies from the University of California at Berkeley.